‘Take a Photograph’: Big Survival Gain in EGFR-Mutant NSCLC

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced EGFR-mutant NSCLC, but the combination comes with more toxicities.
Medscape Medical News

source https://www.medscape.com/viewarticle/take-photograph-trial-shows-big-survival-gain-advanced-egfr-2025a10007fr?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?